For a limited time, The Motley Fool Australia is giving away an urgent new investment report outlining our 5 favourite stocks for investors over 50. I’ll be keeping a close eye on the Mesoblast share price at this time.Despite the catalysts that could send the Mesoblast share price soaring, I don’t think it would be prudent to jump ahead and buy shares in the company hoping for positive results. The product is currently undergoing Phase 3 trials in the United States on COVID-19 patients with acute respiratory distress syndrome.Ryoncil is already in a number of other clinical trials targeted at reducing inflammatory conditions in patients with steroid-refractory acute graft versus host disease (SR-aGVHD).There are two important catalysts in the near future that could send the Mesoblast share price soaring. The company made According to Mesoblast, Ryonsil is design to counteract the inflammatory process induced by COVID-19 by neutralising inflammation. Mesoblast remains unproven, but if the results from the first 12 patients treated with remestemcel-L hold up in larger populations, then it could offer a promising treatment for the most significant cause of COVID-19 deaths. The Data Safety Monitoring Board (DSMB) has set a date in early September to review the data and will inform Mesoblast on whether further trials should proceed.The second catalyst is closer and pertains to Ryoncil’s use in treating children with SR-aGVHD.
Join the HotCopper ASX share market forum today for free. Stock Market Since then, the Mesoblast share price has struggled to gain any traction and was eventually dropped out of the Index. The cell therapy is based on allogeneic mesenchymal stem cells (MSCs), which play a crucial role supporting normal biological functions. About Us Get the latest Mesoblast Limited (MESO) stock news and headlines to help you in your trading and investing decisions. So far, says Itescu, Mesoblast’s treatment has been tested in clinical trials in over 1,100 graft-vs-host patients. Cumulative Growth of a $10,000 Investment in Stock AdvisorMesoblast Soars 219% on Promising COVID-19 Clinical Trial Data @themotleyfool #stocks $MESO For more information please see our The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214Nikhil Gangaram is currently studying dentistry, however, his first love is the stockmarket which he believes to be the greatest wealth generator in the world. Given the current state of the world, that track record might do little to deter health systems desperate for solutions. The company made headlines in April after it announced promising results for … Find the investing style that's right for you. (TMFBlacknGold) If remestemcel-L helps to combat the body's inflammatory responses, then it could help to significantly reduce fatal outcomes related to COVID-19.Many companies have attempted to develop stem cell therapies for a range of diseases. Investing Basics The first is the interim analysis of Ryoncil’s Phase 3 trials in ventilator dependent COVID-19 patients. Nikhil has extensive experience in financial markets with a background in economics and having worked as an Australian equities trader for a proprietary firm. The immunomodulation aspect of MSCs, and possibly remestemcel-L, is what might explain the encouraging results from the trial of COVID-19 patients in New York City. By AAP Read more Business News Maxx has been a contributor to Fool.com since 2013. However, since late-March, the Mesoblast share price has surged more than 314% on the back of a potential treatment for Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases. Mesoblast Soars 219% on Promising COVID-19 Clinical Trial Data The small-scale study, including just 12 patients, could signal big potential for the stem cell company's drug candidate. *This Service provides only general, and not personalised financial advice, and has not taken your personal circumstances into account. Although there may be promising data, investors need to factor in the risk that Mesoblast’s clinical trials fail to reach their endpoint. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.Although the results are from only 12 people, the outcomes are remarkable. Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. MSCs secrete molecules that trigger blood vessel regeneration, repair tissues in the heart and brain, and moderate the immune system. Nikhil hopes to help readers become better investors by focusing on stock selection and risk management.© 2009 - 2020 The Motley Fool Australia Pty Ltd. All rights reserved.ACN: 146 988 052 | Australian Financial Services Licence (AFSL): 400691 See you at the top! Returns as of 09/02/2020.
May 7, 2020 Latest News Mesoblast (ASX:MSB) says the first patients have been dosed in its 300-patient randomised placebo-controlled Phase 2/3 trial in the US of its allogeneic cellular medicine remestemcel-L in COVID-19 infected patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support. Mesoblast has reported a full year net profit of $90.6 million after the regenerative medicine company formed a major strategic alliance. The company is scheduled to meet with the US Food and Drug Administration (FDA) on 13 August. See our latest analysis for Mesoblast . The consensus price target fell 23% to AU$3.98, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook. Let's conquer your financial goals together...faster. However, if the company achieves regulatory approval and can manufacture its products at a cost-effective price, it could become a biotech giant.When investing expert Scott Phillips has a stock tip, it can pay to listen.